Reuters logo
BRIEF-Catabasis Pharmaceuticals Q2 loss per share $0.32
2017年8月10日 / 晚上8点20分 / 1 个月前

BRIEF-Catabasis Pharmaceuticals Q2 loss per share $0.32

Aug 10 (Reuters) - Catabasis Pharmaceuticals Inc

* Catabasis Pharmaceuticals reports second quarter 2017 financial results and reviews business progress

* Q2 loss per share $0.32

* Q2 earnings per share view $-0.40 -- Thomson Reuters I/B/E/S

* Catabasis Pharmaceuticals Inc - ‍continue to advance open-label extension and expect to share 24-week edasalonexent results in Q3

* Catabasis Pharmaceuticals Inc - ‍phase 3 clinical trial plan for edasalonexent in second half of 2017​

* Catabasis Pharmaceuticals Inc - ‍as of June 30, cash and cash equivalents of $29.4 million, versus $31.8 million last quarter

* Catabasis Pharmaceuticals Inc - ‍Catabasis expects that its current operating plan provides for cash to fund operations through August, 2018​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below